Landmarks
Company
established
Parsian Pharma Group was initially inspired by the dedication, mentoring, and leadership of the late Dr. Abbas Shafiee. Established in 2009 at the Avicenna National Biotechnology Park, Parsian Pharmaceutical Company aimed to address the domestic market’s need for high-tech Active Pharmaceutical Ingredients (APIs) and oncology medications. This mission was driven by the collaborative knowledge and practical expertise of distinguished scientific members from the pharmacy faculty of the Tehran University of Medical Sciences (TUMS).
Quality
Targets
As its first project, the company embarked on the production of Imatinib Mesylate, a compound with extensive applications in cancer treatment. In 2011, the company successfully synthesized and supplied it to pharmaceutical companies for finished product formulation.
Simultaneously, the Quality Control Laboratory was outfitted with state-of-the-art and highly precise instruments and facilities. Knowledgeable and skilled professionals were recruited across key domains, including Quality Control (QC), Synthesis, Quality Assurance (QA), and Research and Development (R&D). Building on this foundation, the company went on to successfully produce and present two additional medications—Letrozole, used in breast cancer treatment, and Riluzole, utilized for managing amyotrophic lateral sclerosis (ALS)—in full compliance with the most stringent international standards for synthesis.
Accomplished
GMP
In 2015, Parsian Pharmaceutical Company achieved two invaluable certifications: the Iranian GMP Export Certificate and the Iranian GMP Production Certificate, awarded by the Food and Drug Administration. These certifications were granted following rigorous inspections by FDA experts and were a testament to the company’s commitment to its visions and mission. As a result, Parsian Pharmaceutical Company became the first and only manufacturer in Iran to produce hazardous Active Pharmaceutical Ingredients (APIs) in compliance with the international standards set by the Food and Drug Administration.
Production
Development
In 2017, to expand its product portfolio and increase production capacity, the company established a factory in the Baharestan industrial zone. In line with this initiative, the company designed and procured state-of-the-art equipment that adhered to current global standards, with a particular focus on meeting the specialized requirements for the production of hazardous Active Pharmaceutical Products.
Additionally, recognizing the challenges associated with hazardous product manufacturing and the limited facilities available to finished-product companies, the company prioritized the development of a granule production line. This initiative aimed to address the concerns of finished-product manufacturers and simplify the drug formulation process. Consequently, alongside the design and equipping of the production line for hazardous Active Pharmaceutical Ingredients, the granule production line was also meticulously designed and equipped to meet these needs.
Establishment
of New Production Site
Finally, in 2019, a new production site became operational, marking a significant milestone for the company. That same year, Parsian Pharmaceutical Company successfully obtained the Iranian GMP certification for three production lines: hazardous, general, and granular Active Pharmaceutical Ingredients (APIs). This achievement was granted by the Food and Drug Administration, further solidifying the company’s commitment to maintaining the highest industry standards.
Covering
Domestic Needs
In 2021 and continuing to the present, Parsian Pharmaceutical Company has prioritized the production of Active Pharmaceutical Ingredients (APIs) and granules for anti-cancer, diabetes, multiple sclerosis (MS), and cardiovascular medications. By leveraging its extensive hands-on experience, the company has achieved self-sufficiency for the nation in these critical areas.
Additionally, as a knowledge-based organization, Parsian Pharmaceutical Company remains committed to its core mission of focusing on Research and Development (R&D) and introducing innovative products to the market. Currently, the company has over 20 active projects in the R&D and analysis phases, which are undergoing thorough evaluation and preparation for industrialization. These projects will be launched into the domestic market based on national priorities and needs, following the fulfillment of necessary standards.
Entering
the New Era
Parsian Pharma is strategically positioning itself as a leading player in the domestic market by advancing into the high-tech drug sector, with a strong focus on peptide drugs. Simultaneously, the company is actively preparing to expand its presence on the global stage, with several preliminary initiatives already underway.